Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Spindle Assembly Checkpoint02:19

The Spindle Assembly Checkpoint

3.9K
The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
3.9K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
What is the Immune System?01:38

What is the Immune System?

129.7K
Overview
129.7K
Humoral Immune Responses01:36

Humoral Immune Responses

84.0K
Overview
84.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

676
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
676
Sustainable Development01:43

Sustainable Development

15.1K
As the human population continues to grow and use resources, we must be mindful of our planet’s natural limits. Sustainable development provides a pathway to maintain and improve human life now while also ensuring that future generations will have the resources that they need. The long-term success of sustainability efforts rests on understanding the interplay between human actions and ecological systems.
15.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment patterns and safety of adjuvant therapy after chemoimmunotherapy for early-stage triple-negative breast cancer: real-world data from the Neo-Real/GBECAM 0123 study.

Breast cancer research and treatment·2026
Same author

Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Real-World Evidence From a Large Brazilian Cohort (GBECAM 0520).

JCO oncology practice·2026
Same author

Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123.

NPJ breast cancer·2026
Same author

Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study.

Breast (Edinburgh, Scotland)·2025
Same author

Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitors.

The oncologist·2025
Same author

Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study.

Breast (Edinburgh, Scotland)·2025

Related Experiment Video

Updated: Feb 5, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.8K

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology.

Denis L Jardim1, Débora de Melo Gagliato1, Razelle Kurzrock2

  • 11 Hospital Sirio Libanes, Sao Paulo, Brazil.

Integrative Cancer Therapies
|September 20, 2018
PubMed
Summary

Immune checkpoint inhibitors are rapidly developed and approved. Early phase I trials effectively predict efficacy and safety, ensuring patient safety during development.

Keywords:
FDAcheckpoint inhibitorsdrug developmentimmunotherapyphase I trials

More Related Videos

Evaluation of the Spindle Assembly Checkpoint Integrity in Mouse Oocytes
10:09

Evaluation of the Spindle Assembly Checkpoint Integrity in Mouse Oocytes

Published on: September 13, 2022

2.6K
Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.6K

Related Experiment Videos

Last Updated: Feb 5, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.8K
Evaluation of the Spindle Assembly Checkpoint Integrity in Mouse Oocytes
10:09

Evaluation of the Spindle Assembly Checkpoint Integrity in Mouse Oocytes

Published on: September 13, 2022

2.6K
Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

21.6K

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trial Design

Background:

  • Immunotherapies, particularly immune checkpoint inhibitors, are crucial in cancer treatment.
  • These novel agents are approved rapidly, often through expedited regulatory pathways.
  • Traditional drug development models are being adapted for these advanced therapies.

Purpose of the Study:

  • To analyze the accelerated development of immune checkpoint inhibitors.
  • To evaluate the predictive value of early-phase (Phase I) clinical trials for efficacy and safety.
  • To update recent regulatory approvals for these agents.

Main Methods:

  • Retrospective analysis of clinical trial data for immune checkpoint inhibitors.
  • Comparison of development timelines against previous anticancer therapies.
  • Assessment of dose-finding (Phase I) data for predicting outcomes in later cohorts.

Main Results:

  • Immune checkpoint inhibitors show faster development cycles than prior anticancer drugs.
  • All approved agents received expedited Food and Drug Administration (FDA) programs.
  • Phase I trial data reliably predict efficacy and safety, with low treatment-related mortality.

Conclusions:

  • The development pathway for immune checkpoint inhibitors is significantly accelerated.
  • Phase I trials are effective in predicting the clinical performance of these immunotherapies.
  • Current development models ensure patient safety throughout the drug evaluation process.